Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 15/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL125822 | 0.93 | CCR2 (0.62) | CCR2CYP3A4CYP2C9KCNH2JAK1 | |
| SCHEMBL1762576 | 0.91 | CCR2 (0.76) | CCR2CYP3A4CYP2C9KCNH2JAK1 | |
| SCHEMBL1762530 | 0.87 | CCR2 (0.61) | CCR2CYP3A4CYP2C9KCNH2JAK1 | |
| SCHEMBL12594931 | 0.86 | CCR2 (0.81) | CCR2CYP3A4CYP2C9JAK1 | |
| SCHEMBL1762472 | 0.86 | CCR2 (0.71) | CCR2CYP3A4CYP2C9JAK1 | |
| SCHEMBL12594314 | 0.86 | CCR2 (0.64) | CCR2CYP3A4CYP2C9JAK1 | |
| SCHEMBL12648637 | 0.85 | CYP3A4 (0.53) | CCR2CYP3A4CYP2C9 | |
| SCHEMBL305581 | 0.84 | CYP2C9 (0.63) | CCR2CYP3A4CYP2C9KCNH2 | |
| SCHEMBL12595006 | 0.84 | CCR2 (0.72) | CCR2CYP3A4CYP2C9JAK1 | |
| SCHEMBL1762510 | 0.83 | CYP3A4 (0.64) | CCR2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170095458-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2017-04-06 | — | — | US | disclosed |
| US-20140031348-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX INC (US) | 2014-01-30 | — | — | US | disclosed |
| US-8519135-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20110118248-A1 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031348-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CCR2, CCR9, CCR1 | CCR2 1/4885CYP3A4 1934/4885CYP2C9 192/4885 |
| US-20170095458-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CCR2, CCR9, CCR1 | CCR2 1/4885CYP3A4 1934/4885CYP2C9 192/4885 |
| US-20110118248-A1 | Heteroaryl sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | CCR2 1/4885CYP3A4 1934/4885CYP2C9 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.